

**FISCAL IMPACT OF PROPOSED LEGISLATION**

80th Oregon Legislative Assembly – 2019 Regular Session  
Legislative Fiscal Office

**Measure: HB 2689 - 1**

*Only Impacts on Original or Engrossed  
Versions are Considered Official*

Prepared by: Kim To  
Reviewed by: Tom MacDonald, John Borden  
Date: April 4, 2019

**Measure Description:**

Requires Oregon Health Authority to design and, with federal approval, implement program to import wholesale prescription drugs from Canada.

**Government Unit(s) Affected:**

Oregon Health Authority (OHA), Department of Justice (DOJ)

**Analysis:**

This fiscal impact statement is for the purpose of transmitting the measure from the House Committee on Health Care to the Joint Committee on Ways and Means.

The measure with the -1 amendment directs the Oregon Health Authority (OHA), in consultation with stakeholders and appropriate federal officials, to design a wholesale prescription drug importation program in which OHA acts as a licensed drug wholesaler or contracts with a licensed drug wholesaler to import prescription drugs from Canada. The prescription drugs imported must be from high quality Canadian prescription drug suppliers that are subject to regulation under and are in full compliance with the laws of Canada or one or more Canadian provinces. The prescription drugs must also meet the requirements for safety and effectiveness adopted by the United States Department of Health and Human Services and other requirements specified by the measure. The wholesale prescription drug importation program must be in operation no later than six months after the United States Department of Health and Human Services certifies the program.

The measure removes language that prohibits the Oregon Prescription Drug Program administrator from contracting with a pharmacy manager or establish a state-managed wholesale or retail drug distribution or dispensing system. The measure specifies that the administer may not require pharmacies to maintain or allocate separate inventories for prescription drugs dispensed through the program, except as necessary to enter into or carry out an agreement for the bulk purchasing of prescription drugs.

The measure requires the Attorney General, in consultation with OHA, to identify the potential for and monitor for anticompetitive behavior by industries affected by the wholesale prescription drug importation program.

The measure is anticipated to have an impact on the Oregon Health Authority and the Department of Justice.

A more complete fiscal analysis on the measure will be prepared as the measure is considered in the Joint Committee on Ways and Means.

Further Analysis Required